Upacicalcet Sodium Injection 25μg (Upasita® / ウパシタ静注透析用25μgシリンジ)

JPY ¥14,000

Japanese Calcium Receptor Agonist (Upacicalcet Sodium Hydrate 25μg/1mL). Intravenous injection for secondary hyperparathyroidism in hemodialysis patients. 1mL x 10 syringes. Mfd. by Sanwa Kagaku Kenkyusho Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥12,880
10 - 19 12% JPY ¥12,320
20 + 18% JPY ¥11,480
SKU: UPA-25-INJ Category:

Description

Product Overview / 商品概要

Upasita IV Injection Syringe for Dialysis 25μg (ウパシタ静注透析用25μgシリンジ)
Generic: Upacicalcet Sodium Hydrate / ウパシカルセトナトリウム水和物
Therapeutic Category: Calcium Receptor Agonist / カルシウム受容体作動薬
Manufactured by: Sanwa Kagaku Kenkyusho Co., Ltd. / 株式会社三和化学研究所

Composition & Specification / 組成・規格

Active Ingredient: Upacicalcet Sodium 25μg per 1 syringe (1mL) / ウパシカルセトナトリウムとして25μg(1シリンジ1mL中)
Additives: Sodium chloride 8.8mg, Sodium hydrogen phosphate hydrate q.s., Sodium dihydrogen phosphate hydrate q.s. / 塩化ナトリウム 8.8mg、リン酸水素ナトリウム水和物 適量、リン酸二水素ナトリウム水和物 適量
Appearance: Colorless clear solution, pH 6.0–7.0, osmotic pressure ratio approx. 1 (relative to physiological saline)
外観: 無色澄明の液、pH 6.0〜7.0、浸透圧比 約1(生理食塩液対比)

Indications / 効能効果

EN: Secondary hyperparathyroidism in patients undergoing hemodialysis
JA: 血液透析下の二次性副甲状腺機能亢進症

Dosage and Administration / 用法用量

EN: In adults, the usual starting dose is 25μg of upacicalcet sodium per administration, given 3 times weekly via the venous side of the dialysis circuit at the time of blood return at the end of dialysis. The starting dose may be increased to 50μg per administration based on serum calcium levels. Thereafter, the dose should be adjusted as appropriate within the range of 25–300μg per administration, with close monitoring of the patient’s parathyroid hormone (PTH) and serum calcium levels.
JA: 通常、成人には、ウパシカルセトナトリウムとして、1回25μgを開始用量とし、週3回、透析終了時の返血時に透析回路静脈側に注入する。血清カルシウム濃度に応じて開始用量を1回50μgとすることができる。以後は、患者の副甲状腺ホルモン(PTH)及び血清カルシウム濃度の十分な観察のもと、1回25〜300μgの範囲内で適宜用量を調整する。

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product; pregnant women or women who may be pregnant
JA: 本剤の成分に対し過敏症の既往症のある患者、妊婦又は妊娠している可能性のある女性

Regulatory Information / 規制情報

Approval No.: 30300AMX00281000
Sales Started: August 2021 / 2021年8月
Classification Code: 873999
Storage: Store at 2–8°C / 2〜8℃に保存
Shelf Life: 36 months / 36カ月

Packaging / 包装

Main Package (for sale): 1mL x 10 syringes / 1mL×10シリンジ
Other Available Packages (by special order): 1mL [10 syringes]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Upacicalcet Sodium Injection 25μg (Upasita® / ウパシタ静注透析用25μgシリンジ)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Upacicalcet Sodium Injection 25μg (Upasita®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.